

39. Minar P, Saeed SA, Afreen M, et al. Practical use of infliximab concentration monitoring in pediatric Crohn disease. *J Pediatr Gastroenterol Nutr* 2016; 62: 715–722.
40. Viola F, Civitelli F, Di Nardo G, et al. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. *Am J Gastroenterol* 2009; 104: 2566–2571.
41. Papamichael K, van Stappen T, Vande Castele N, et al. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis. *Clin Gastroenterol Hepatol* 2016; 14: 543–549.
42. Singh N, Rosenthal CJ, Melmed GY, et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2014; 20: 1708–1713.
43. Ding NS, Hart A, de Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease – algorithm for practical management. *Aliment Pharmacol Ther* 2016; 43: 30–51.
44. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. *Gut* 2014; 63: 1721–1727.
45. Amin A, Prosser C, Kroeker K, et al. Using infliximab trough levels and fecal calprotectin levels together to guide clinical decisions has the potential to improve outcomes in inflammatory bowel disease patients on maintenance infliximab therapy. *Gastroenterology* 2016; 150: S422.
46. Ungar B, Chowder Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. *Gut* 2014; 63: 1258–1264.
47. Steenholdt C, Frederiksen MT, Bendtzen K et al. Time course and clinical implications of development of antibodies against adalimumab in patients with inflammatory bowel disease. *J Clin Gastroenterol* 2015; 50: 483–489.
48. Papamichael K, Vande Castele N, Billiet T, et al. Early therapeutic drug monitoring for prediction of short-term mucosal healing in patients with ulcerative colitis treated with infliximab. *Gastroenterology* 2015; 148: S848.
49. Bortlík M, Ďuricová D, Malíčková K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. *JCC* 2013; 7: 736–743.
50. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. *Gut* 2007; 56: 1226–1231.
51. Papamichael K, Vande Castele N, Ferrante M, et al. Therapeutic drug monitoring during induction of anti-tumor necrosis factor therapy in inflammatory bowel disease: defining a therapeutic window. *Inflamm Bowel Dis* 2017; 23: 1510–1515.
52. Pariente B, de Chambrun GP, Krzysiek R, et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2011; 18: 1199–1206.
53. Roblin X, Williet N, Peyrin-Biroulet L. Thiopurine metabolism in the area of combination therapy. *Inflamm Bowel Dis* 2016; 22: 1496–1501.
54. Del Tedesco E, Paul S, Marotte H. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: A prospective study. *DDW* 2016, oral presentation 693.
55. D'Haens G, Vermeire S, Lambrecht G, et al. OP029 Drug-concentration versus symptom-driven dose adaptation of infliximab in patients with active Crohn's disease: a prospective, randomised, multicentre trial (Tailorix). *ECCO*; 2016.
56. Papamichael K, Chachu KA, Vajravelu RK, et al. Improved long term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. *Clin Gastroenterol Hepatol* 2017; 15: 1580–1588.
57. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. *Gut* 2014; 63: 919–927.
58. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn's disease patients failing infliximab. *Dig Dis Sci* 2015; 60: 2762–2770.
59. Vande Castele N, Khanna R, Levesque BG, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. *Gut* 2015; 64: 1539–1545.
60. Flamant M, Roblin X. Could therapeutic drug monitoring of anti-TNF-alpha be useful to consider a de-escalation of treatment? *Expert Opin Biol Ther* 2015; 15: 1657–1660.
61. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. *Gastroenterology* 2012; 142: 63–70.
62. Papamichael K, Vande Castele N, Gils A, et al. Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission. *Clin Gastroenterol Hepatol* 2015; 13: 1103–1110.
63. Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2013; 11: 444–447.
64. D'Haens G, Vermeire S, Lambrecht G, et al. GETAID. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn's disease. *Gastroenterology* 2018; 154: 1343–1351.
65. Papamichael K, Vajravelu RK, Vaughn BP, et al. Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease. *J Crohn's Colitis* 2018; 12: 804–810.
66. Bortlík M, Ďuricová D, Machková N, et al. Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant woman with inflammatory bowel disease on long-term outcome of exposed children. *Inflamm Bowel Dis* 2014; 20: 495–501.
67. Steenholdt C, Bendtzen K, Brynskov J, et al. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. *Inflamm Bowel Dis* 2016; 22: 1999–2015.
68. Steenholdt C, Brynskov J, Thomsen OO, et al. Implications of infliximab treatment failure and influence of personalized treatment on patient-reported health-related quality of life and productivity outcomes in Crohn's disease. *J Crohn's Colitis* 2015; 9: 1032–1042.
69. Velayos FS, Kahn JG, Sandborn WJ, et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. *Clin Gastroenterol Hepatol* 2013; 11: 654–666.
70. Negoescu DM, Enns EA, Swanhorst B, et al. Proactive vs reactive Therapeutic drug monitoring of infliximab in Crohn's disease: A cost-effectiveness analysis in a simulated cohort. *Inflamm Bowel Dis* 2019; 50: 1–9.